rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    STTK
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF), Icon (ICLR) and Shattuck Labs (STTK)

      Detailed price information for Shattuck Labs Inc (STTK-Q) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailSTTK
      Leerink Partners Keeps Their Buy Rating on Shattuck Labs (STTK)

      Detailed price information for Shattuck Labs Inc (STTK-Q) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailSTTK
      Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology
      Oct 12Seeking AlphaNKTRPTGXSTTK
      UBS Initiates Shattuck Labs at Buy With $17 Price Target
      Oct 12Yahoo FinanceSTTK
      UBS initiates Shattuck Labs stock with buy rating on drug advantage
      Oct 12Investing.comSTTK
      Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Shattuck Labs (STTK) and Arcus Biosciences (RCUS)

      Detailed price information for Arcus Biosciences Inc (RCUS-N) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailSTTKEHCRCUS
      Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Atricure (ATRC)

      Detailed price information for Atricure Inc (ATRC-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailATRCSTTK
      Shattuck Labs (STTK) Receives a Buy from Leerink Partners

      Detailed price information for Shattuck Labs Inc (STTK-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailSTTK
      Needham raises Shattuck Labs stock price target on HS trial plans
      Oct 2Investing.comSTTK
      Update: Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating
      Oct 1Yahoo FinanceSTTK
      Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating
      Oct 1Yahoo FinanceSTTK
      Shattuck Labs plans phase 2 trial for SL-325 in hidradenitis suppurativa
      Oct 1Investing.comSTTK
      Shattuck Labs at Wells Fargo conference: DR3 bet takes center stage
      Sep 8Investing.comSTTKWFC
      Shattuck Labs Stock: A Receptor-Side Bet On The TL1A Boom (NASDAQ:STTK)

      Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing oncology. Read why STTK stock is a buy.

      Sep 1Seeking AlphaSTTK
      Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
      Sep 1Seeking AlphaSTTK
      What Shattuck Labs Stock Topped the Market on Monday

      Two analysts weighed in with new takes on the biotech.

      Aug 24Yahoo FinanceSTTK
      Raymond James initiates Shattuck Labs stock with strong buy rating
      Aug 24Investing.comSTTK
      Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target

      Shattuck Labs (STTK) has an average rating of buy and mean price target of $15, according to analyst

      Aug 24Yahoo FinanceSTTK

      This is the newest page. Registered accounts read further back.